{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:54Z","timestamp":1791912474545,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10072-024-07577-7","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T05:01:45Z","timestamp":1720155705000},"page":"5671-5683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Marco","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Sgarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"7577_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000279334","volume":"34","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Sneddon S, de Vries CS (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 34:171\u2013183. https:\/\/doi.org\/10.1159\/000279334","journal-title":"Neuroepidemiology"},{"key":"7577_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1196\/annals.1254.053","volume":"998","author":"LH Phillips","year":"2003","unstructured":"Phillips LH (2003) The epidemiology of myasthenia gravis. Ann N Y Acad Sci 998:407\u2013412. https:\/\/doi.org\/10.1196\/annals.1254.053","journal-title":"Ann N Y Acad Sci"},{"key":"7577_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"A-M Bubuioc","year":"2021","unstructured":"Bubuioc A-M, Kudebayeva A, Turuspekova S et al (2021) The epidemiology of myasthenia gravis. J Med Life 14:7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"7577_CR4","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med 10:2235. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"7577_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","volume":"153","author":"D Grob","year":"1953","unstructured":"Grob D (1953) Course and management of myasthenia gravis. J Am Med Assoc 153:529\u2013532. https:\/\/doi.org\/10.1001\/jama.1953.02940230001001","journal-title":"J Am Med Assoc"},{"key":"7577_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T (1987) The Course of Myasthenia Gravis and Therapies Affecting Outcomea. Ann N Y Acad Sci 505:472\u2013499. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb51317.x","journal-title":"Ann N Y Acad Sci"},{"key":"7577_CR7","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94:e1171\u2013e1180. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"key":"7577_CR8","doi-asserted-by":"publisher","first-page":"30649","DOI":"10.1073\/pnas.2007206117","volume":"117","author":"R Jiang","year":"2020","unstructured":"Jiang R, Hoehn KB, Lee CS et al (2020) Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proc Natl Acad Sci 117:30649\u201330660. https:\/\/doi.org\/10.1073\/pnas.2007206117","journal-title":"Proc Natl Acad Sci"},{"key":"7577_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","volume":"15","author":"C Bernard","year":"2016","unstructured":"Bernard C, Frih H, Pasquet F et al (2016) Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 15:82\u201392. https:\/\/doi.org\/10.1016\/j.autrev.2015.09.005","journal-title":"Autoimmun Rev"},{"key":"7577_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"7577_CR11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"7577_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SMJ.0b013e31815d4398","volume":"101","author":"EM Bershad","year":"2008","unstructured":"Bershad EM, Feen ES, Suarez JI (2008) Myasthenia gravis crisis. South Med J 101:63\u201369. https:\/\/doi.org\/10.1097\/SMJ.0b013e31815d4398","journal-title":"South Med J"},{"key":"7577_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1756285615605700","volume":"8","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord 8:316\u2013327. https:\/\/doi.org\/10.1177\/1756285615605700","journal-title":"Ther Adv Neurol Disord"},{"key":"7577_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","volume":"36","author":"DB Drachman","year":"2016","unstructured":"Drachman DB (2016) Myasthenia Gravis. Semin Neurol 36:419\u2013424. https:\/\/doi.org\/10.1055\/s-0036-1586265","journal-title":"Semin Neurol"},{"key":"7577_CR15","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"7577_CR16","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86:255\u2013260","journal-title":"Yale J Biol Med"},{"key":"7577_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"7577_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"7577_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"7577_CR20","unstructured":"Stewart D, Shamdasani P (1990) Focus groups: Theory and practice. Applied social research methods series, Thousand Oaks, CA: SAGE publications"},{"key":"7577_CR21","unstructured":"Bezzi C (2013) Fare ricerca con i gruppi. Guida all\u2019utilizzo di focus group, brainstorming, Delphi e altre tecniche. Franco Angeli editore.\u00a0https:\/\/www.francoangeli.it\/Libro\/Fare-ricerca-con-i-gruppi-Guida-all%27utilizzo-di-focus-group,-brainstorming,-Delphi-e-altre-tecniche?Id=21239. Accessed 3 June 2024"},{"key":"7577_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70:327\u2013334. https:\/\/doi.org\/10.1016\/s0003-4975(00)01595-2","journal-title":"Ann Thorac Surg"},{"key":"7577_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1749-6632.2012.06771.x","volume":"1274","author":"F Baggi","year":"2012","unstructured":"Baggi F, Mantegazza R, Antozzi C, Sanders D (2012) Patient registries: useful tools for clinical research in myasthenia gravis. Ann N Y Acad Sci 1274:107\u2013113. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06771.x","journal-title":"Ann N Y Acad Sci"},{"key":"7577_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S et al (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22:1056\u20131061. https:\/\/doi.org\/10.1111\/ene.12703","journal-title":"Eur J Neurol"},{"key":"7577_CR25","doi-asserted-by":"publisher","unstructured":"Wolfe GI, Herbelin L, Nations SP, et al (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","DOI":"10.1212\/wnl.52.7.1487"},{"key":"7577_CR26","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","volume":"64","author":"RS Bedlack","year":"2005","unstructured":"Bedlack RS, Simel DL, Bosworth H et al (2005) Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64:1968\u20131970. https:\/\/doi.org\/10.1212\/01.WNL.0000163988.28892.79","journal-title":"Neurology"},{"key":"7577_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"7577_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.24911","volume":"53","author":"C Antozzi","year":"2016","unstructured":"Antozzi C, Brenna G, Baggi F et al (2016) Validation of the Besta Neurological Institute rating scale for myasthenia gravis. Muscle Nerve 53:32\u201337. https:\/\/doi.org\/10.1002\/mus.24911","journal-title":"Muscle Nerve"},{"key":"7577_CR29","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 Study Group (2010) The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology 74:1434\u20131440. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e","journal-title":"Neurology"},{"key":"7577_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM et al (2012) Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45:909\u2013917. https:\/\/doi.org\/10.1002\/mus.23330","journal-title":"Muscle Nerve"},{"key":"7577_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M et al (2016) Development and validation of the Myasthenia Gravis Impairment Index. Neurology 87:879\u2013886. https:\/\/doi.org\/10.1212\/WNL.0000000000002971","journal-title":"Neurology"},{"key":"7577_CR32","first-page":"289","volume":"59","author":"S Aurangzeb","year":"2009","unstructured":"Aurangzeb S, Tariq M, Irshad M et al (2009) Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc 59:289\u2013292","journal-title":"J Pak Med Assoc"},{"key":"7577_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang L, Wang S, Yang H et al (2021) No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients. Brain Behav 11:e02203. https:\/\/doi.org\/10.1002\/brb3.2203","journal-title":"Brain Behav"},{"key":"7577_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","volume":"30","author":"A Meisel","year":"2023","unstructured":"Meisel A, Baggi F, Behin A et al (2023) Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal. Eur J Neurol 30:266\u2013282. https:\/\/doi.org\/10.1111\/ene.15565","journal-title":"Eur J Neurol"},{"key":"7577_CR35","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP et al (2020) \u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y","journal-title":"J Neurol"},{"key":"7577_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00131402-200209000-00009","volume":"4","author":"RS Bedlack","year":"2002","unstructured":"Bedlack RS, Sanders DB (2002) On the concept of myasthenic crisis. J Clin Neuromuscul Dis 4:40\u201342. https:\/\/doi.org\/10.1097\/00131402-200209000-00009","journal-title":"J Clin Neuromuscul Dis"},{"key":"7577_CR37","volume-title":"Neurological and Neurosurgical Intensive Care","author":"AH Ropper","year":"2004","unstructured":"Ropper AH (2004) Neurological and Neurosurgical Intensive Care. Lippincott Williams & Wilkins"},{"key":"7577_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42466-019-0023-3","volume":"1","author":"H Stetefeld","year":"2019","unstructured":"Stetefeld H, Schroeter M (2019) SOP myasthenic crisis. Neurol Res Pract 1:19. https:\/\/doi.org\/10.1186\/s42466-019-0023-3","journal-title":"Neurol Res Pract"},{"key":"7577_CR39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/wnl.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y et al (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253\u20131260. https:\/\/doi.org\/10.1212\/wnl.48.5.1253","journal-title":"Neurology"},{"key":"7577_CR40","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1749-6632.1981.tb33765.x","volume":"377","author":"MS Cohen","year":"1981","unstructured":"Cohen MS, Younger D (1981) Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci 377:670\u2013677. https:\/\/doi.org\/10.1111\/j.1749-6632.1981.tb33765.x","journal-title":"Ann N Y Acad Sci"},{"key":"7577_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484\u2013505. https:\/\/doi.org\/10.1002\/mus.20030","journal-title":"Muscle Nerve"},{"key":"7577_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ (2006) Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 13:1006\u20131010. https:\/\/doi.org\/10.1016\/j.jocn.2005.12.041","journal-title":"J Clin Neurosci"},{"key":"7577_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho S-M, Li Y (2023) Myasthenic crisis. Muscle Nerve 68:8\u201319. https:\/\/doi.org\/10.1002\/mus.27832","journal-title":"Muscle Nerve"},{"key":"7577_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM197201062860104","volume":"286","author":"JR Warmolts","year":"1972","unstructured":"Warmolts JR, Engel WK (1972) Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 286:17\u201320. https:\/\/doi.org\/10.1056\/NEJM197201062860104","journal-title":"N Engl J Med"},{"key":"7577_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of Myasthenia Gravis. Neurol Clin 36:311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"key":"7577_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI (2012) Myasthenia gravis. Semin Neurol 32:215\u2013226. https:\/\/doi.org\/10.1055\/s-0032-1329200","journal-title":"Semin Neurol"},{"key":"7577_CR47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291\u2013298. https:\/\/doi.org\/10.1002\/ana.410150316","journal-title":"Ann Neurol"},{"key":"7577_CR48","doi-asserted-by":"publisher","unstructured":"Johns T (1987) Long-term corticosteroid treatment of myasthenia gravis. Annals of the New York Academy of Sciences 505:. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb51325.x","DOI":"10.1111\/j.1749-6632.1987.tb51325.x"},{"key":"7577_CR49","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group Neurol 50:1778\u20131783. https:\/\/doi.org\/10.1212\/wnl.50.6.1778","journal-title":"Myasthenia Gravis Study Group Neurol"},{"key":"7577_CR50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400\u2013406. https:\/\/doi.org\/10.1212\/01.wnl.0000312374.95186.cc","journal-title":"Neurology"},{"key":"7577_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"Muscle Study Group","year":"2008","unstructured":"Muscle Study Group (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394\u2013399. https:\/\/doi.org\/10.1212\/01.wnl.0000312373.67493.7f","journal-title":"Neurology"},{"key":"7577_CR52","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT et al (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719\u2013724. https:\/\/doi.org\/10.1056\/NEJM198703193161205","journal-title":"N Engl J Med"},{"key":"7577_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nikhar NK, Massey JM, Sanders DB (2000) Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 55:448\u2013450. https:\/\/doi.org\/10.1212\/WNL.55.3.448","journal-title":"Neurology"},{"key":"7577_CR54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s004150050141","volume":"244","author":"DM Bonifati","year":"1997","unstructured":"Bonifati DM, Angelini C (1997) Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 244:542\u2013547. https:\/\/doi.org\/10.1007\/s004150050141","journal-title":"J Neurol"},{"key":"7577_CR55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1681\/ASN.V12162","volume":"1","author":"JB Kopp","year":"1990","unstructured":"Kopp JB, Klotman PE (1990) Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1:162\u2013179. https:\/\/doi.org\/10.1681\/ASN.V12162","journal-title":"J Am Soc Nephrol"},{"key":"7577_CR56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mus.24536","volume":"52","author":"KA Buzzard","year":"2015","unstructured":"Buzzard KA, Meyer NJ, Hardy TA et al (2015) Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 52:204\u2013210. https:\/\/doi.org\/10.1002\/mus.24536","journal-title":"Muscle Nerve"},{"key":"7577_CR57","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"7577_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00314245","volume":"235","author":"R Mantegazza","year":"1988","unstructured":"Mantegazza R, Antozzi C, Peluchetti D et al (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 235:449\u2013453. https:\/\/doi.org\/10.1007\/BF00314245","journal-title":"J Neurol"},{"key":"7577_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0022-510x(97)05370-7","volume":"150","author":"MB Bromberg","year":"1997","unstructured":"Bromberg MB, Wald JJ, Forshew DA et al (1997) Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 150:59\u201362. https:\/\/doi.org\/10.1016\/s0022-510x(97)05370-7","journal-title":"J Neurol Sci"},{"key":"7577_CR60","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/TCRM.S14015","volume":"7","author":"S Sathasivam","year":"2011","unstructured":"Sathasivam S (2011) Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag 7:313\u2013323. https:\/\/doi.org\/10.2147\/TCRM.S14015","journal-title":"Ther Clin Risk Manag"},{"key":"7577_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/WNL.0000000000003570","volume":"88","author":"DB Sanders","year":"2017","unstructured":"Sanders DB, Wolfe GI, Narayanaswami P (2017) Author response: International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 88:505\u2013506. https:\/\/doi.org\/10.1212\/WNL.0000000000003570","journal-title":"Neurology"},{"key":"7577_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.594152","volume":"11","author":"Z Fan","year":"2020","unstructured":"Fan Z, Li Z, Shen F et al (2020) Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients. Front Neurol 11:594152. https:\/\/doi.org\/10.3389\/fneur.2020.594152","journal-title":"Front Neurol"},{"key":"7577_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.32117","volume":"146A","author":"A Perez-Aytes","year":"2008","unstructured":"Perez-Aytes A, Ledo A, Boso V et al (2008) In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 146A:1\u20137. https:\/\/doi.org\/10.1002\/ajmg.a.32117","journal-title":"Am J Med Genet A"},{"key":"7577_CR64","doi-asserted-by":"publisher","unstructured":"Wentzell N, Kollhorst B, Reinold J, Haug U (2022) Use of Methotrexate in Girls and Women of Childbearing Age, Occurrence of Methotrexate-Exposed Pregnancies and Their Outcomes in Germany: A Claims Data Analysis. Clin Drug Investig. https:\/\/doi.org\/10.1007\/s40261-022-01227-6","DOI":"10.1007\/s40261-022-01227-6"},{"key":"7577_CR65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208840","journal-title":"Ann Rheum Dis"},{"key":"7577_CR66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1017\/cjn.2021.2","volume":"48","author":"M Alharbi","year":"2021","unstructured":"Alharbi M, Menon D, Barnett C et al (2021) Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Can J Neurol Sci 48:767\u2013771. https:\/\/doi.org\/10.1017\/cjn.2021.2","journal-title":"Can J Neurol Sci"},{"key":"7577_CR67","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ene.14153","volume":"27","author":"CD Kassardjian","year":"2020","unstructured":"Kassardjian CD, Widdifield J, Paterson JM et al (2020) Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol 27:702\u2013708. https:\/\/doi.org\/10.1111\/ene.14153","journal-title":"Eur J Neurol"},{"key":"7577_CR68","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.410150615","volume":"15","author":"AS Witte","year":"1984","unstructured":"Witte AS, Cornblath DR, Parry GJ et al (1984) Azathioprine in the treatment of myasthenia gravis. Ann Neurol 15:602\u2013605. https:\/\/doi.org\/10.1002\/ana.410150615","journal-title":"Ann Neurol"},{"key":"7577_CR69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","volume":"11","author":"K Albazli","year":"2020","unstructured":"Albazli K, Kaminski HJ, Howard JF (2020) Complement Inhibitor Therapy for Myasthenia Gravis. Front Immunol 11:917. https:\/\/doi.org\/10.3389\/fimmu.2020.00917","journal-title":"Front Immunol"},{"key":"7577_CR70","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1474-4422(18)30037-1","volume":"17","author":"RHP de Meel","year":"2018","unstructured":"de Meel RHP, Verschuuren JJGM, Tannemaat MR (2018) Distinct representation of muscle weakness in QMG and MG-ADL. Lancet Neurol 17:204\u2013205. https:\/\/doi.org\/10.1016\/S1474-4422(18)30037-1","journal-title":"Lancet Neurol"},{"key":"7577_CR71","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/acn3.51121","volume":"7","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, O\u2019Brien FL, Yountz M et al (2020) Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol 7:1327\u20131339. https:\/\/doi.org\/10.1002\/acn3.51121","journal-title":"Ann Clin Transl Neurol"},{"key":"7577_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"7577_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR et al (2020) Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Front Neurol 11:556104. https:\/\/doi.org\/10.3389\/fneur.2020.556104","journal-title":"Front Neurol"},{"key":"7577_CR74","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S et al (2021) Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology 96:e610\u2013e618. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","journal-title":"Neurology"},{"key":"7577_CR75","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/acn3.51376","volume":"8","author":"JF Howard","year":"2021","unstructured":"Howard JF, Karam C, Yountz M et al (2021) Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol 8:1398\u20131407. https:\/\/doi.org\/10.1002\/acn3.51376","journal-title":"Ann Clin Transl Neurol"},{"key":"7577_CR76","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/0272989X14539731","volume":"34","author":"D Coyle","year":"2014","unstructured":"Coyle D, Cheung MC, Evans GA (2014) Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making 34:1016\u20131029. https:\/\/doi.org\/10.1177\/0272989X14539731","journal-title":"Med Decis Making"},{"key":"7577_CR77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","volume":"96","author":"F Alashkar","year":"2017","unstructured":"Alashkar F, Vance C, Herich-Terh\u00fcrne D et al (2017) Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol 96:589\u2013596. https:\/\/doi.org\/10.1007\/s00277-017-2924-y","journal-title":"Ann Hematol"},{"key":"7577_CR78","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s10072-022-05922-2","volume":"43","author":"M Mimori","year":"2022","unstructured":"Mimori M, Komatsu T, Maku T et al (2022) Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab. Neurol Sci 43:4081\u20134083. https:\/\/doi.org\/10.1007\/s10072-022-05922-2","journal-title":"Neurol Sci"},{"key":"7577_CR79","doi-asserted-by":"publisher","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L, et al (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. eClinicalMedicine 28:. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100590","DOI":"10.1016\/j.eclinm.2020.100590"},{"key":"7577_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","volume":"2","author":"F Pasqualin","year":"2020","unstructured":"Pasqualin F, Guidoni SV, Ermani M et al (2020) Outcome measures and treatment effectiveness in late onset myasthenia gravis. Neurol Res Pract 2:45. https:\/\/doi.org\/10.1186\/s42466-020-00091-z","journal-title":"Neurol Res Pract"},{"key":"7577_CR81","unstructured":"RCP Soliris (eculizumab) approved on April, 18 2023. https:\/\/medisoc.it\/wp-content\/uploads\/Eculizumab-Soliris-RCP.pdf (Accessed: June 14, 2023)"},{"key":"7577_CR82","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859\u2013866. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x","journal-title":"Am J Transplant"},{"key":"7577_CR83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 56:185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"7577_CR84","doi-asserted-by":"publisher","first-page":"117957352110160","DOI":"10.1177\/11795735211016080","volume":"13","author":"T Mathew","year":"2021","unstructured":"Mathew T, Thomas K, John KS et al (2021) Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country. J Cent Nerv Syst Dis 13:11795735211016080. https:\/\/doi.org\/10.1177\/11795735211016080","journal-title":"J Cent Nerv Syst Dis"},{"key":"7577_CR85","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE et al (2023) Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. Eur J Neurol 30:3854\u20133867. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"key":"7577_CR86","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","volume":"58","author":"G Beecher","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA (2018) Rituximab in refractory myasthenia gravis: Extended prospective study results. Muscle Nerve 58:452\u2013455. https:\/\/doi.org\/10.1002\/mus.26156","journal-title":"Muscle Nerve"},{"key":"7577_CR87","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"7577_CR88","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol 77:974\u2013981. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"7577_CR89","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"M Pasnoor","year":"2010","unstructured":"Pasnoor M, Wolfe GI, Nations S et al (2010) Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 41:370\u2013374. https:\/\/doi.org\/10.1002\/mus.21533","journal-title":"Muscle Nerve"},{"key":"7577_CR90","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","volume":"32","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E et al (2022) Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul Disord 32:664\u2013671. https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006","journal-title":"Neuromuscul Disord"},{"key":"7577_CR91","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","volume":"6","author":"KM Kanth","year":"2016","unstructured":"Kanth KM, Solorzano GE, Goldman MD (2016) PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 6:e17\u2013e19. https:\/\/doi.org\/10.1212\/CPJ.0000000000000202","journal-title":"Neurol Clin Pract"},{"key":"7577_CR92","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.14675","volume":"28","author":"C Tran","year":"2021","unstructured":"Tran C, Biswas A, Mendoza M et al (2021) Performance of different criteria for refractory myasthenia gravis. Eur J Neurol 28:1375\u20131384. https:\/\/doi.org\/10.1111\/ene.14675","journal-title":"Eur J Neurol"},{"key":"7577_CR93","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F et al (2022) Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals Clin Transl Neurol 9:122\u2013131. https:\/\/doi.org\/10.1002\/acn3.51492","journal-title":"Annals Clin Transl Neurol"},{"key":"7577_CR94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","volume":"23","author":"A Simpson","year":"2021","unstructured":"Simpson A, Mowry EM, Newsome SD (2021) Early Aggressive Treatment Approaches for Multiple Sclerosis. Curr Treat Options Neurol 23:19. https:\/\/doi.org\/10.1007\/s11940-021-00677-1","journal-title":"Curr Treat Options Neurol"},{"key":"7577_CR95","doi-asserted-by":"publisher","unstructured":"Simonsen CS, Flemmen H\u00d8, Broch L, et al (2021) Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.\u00a0Front Neurol 12:693017. https:\/\/doi.org\/10.3389\/fneur.2021.693017","DOI":"10.3389\/fneur.2021.693017"},{"key":"7577_CR96","doi-asserted-by":"publisher","unstructured":"Stankiewicz JM, Weiner HL (2020) An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflam 7:. https:\/\/doi.org\/10.1212\/NXI.0000000000000636","DOI":"10.1212\/NXI.0000000000000636"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07577-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:09:34Z","timestamp":1731319774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07577-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7577"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07577-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RM received funding for Travel, Meeting attendance or Advisory Board participation from Alexion, Argenx, Biomarin, Catalyst, SANOFI, Regeneron and UCB.FS received public speaking honoraria from Alexion, argenx, Biogen, Genpharm, Medpharma, Medison Pharma, Mylan, Neopharm Israel, Novartis, Roche, Sanofi, Zai Lab; compensation for advisory boards from Alexion, Almirall, argenx, Astrazeneca, Avexis, Biogen, Forward Pharma, Dianthus, Lexeo Therapeutics, Merk, Novartis GmBh, Reata, Roche, Sandoz, Sanofi, Takeda; consultation fees from Alexion, Dianthus, EPG Comunication Holding ltd, Forward Pharma, Medscape, Novatek,PeerView, Vitaccess; he has been clinical trial principal investigator for Alexion, argenx, Dianthus, Immunovant, Lediant, Novartis, Prilenia, Sanofi.GA declares conference honoraria, advisory board and travel grants from Kedrion, Jannsen, Alnylam, Alexion, Argenx, Takeda.DMB declares advisory board honoraria from Argenx, Alexion, Roche; research support as PI for Roche and Alexion; speaker's Honoraria from Argenx, Alexion, UCB.AE has no competing interests to declare.FH has no competing interests to declare.RL declares lecture fees, advisory board, videointerview, fees for meeting chairing and scientific organization from Summeet, Alexion Pharma Italy, UCB Pharma, Med Stage, Amicus Therapeutics, Alfasigma, ECM network, Healthware group, PTS, Aim Education, Sanofi Genzyme Corporation.EP reports personal fees from Biogen, Roche, Novartis, Alexion and UCB Biopharma outside the submitted work. EP is part of the advisory boards for Biogen, Roche, Alexion, UCB Pharma.CR received honoraria for speaking, advisory boards and compensation for congress participations from Alexion, Argenx, and UCB, outside the submitted work.AS, MS and GP have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}